Although little is known about the effects of currently used myeloma drugs on CAFs, a paper by Celegato et al. showed bortezomib was able to downregulate CD49d and CD44 expression factors that mediate the adhesion of human Hodgkin lymphoma cells to fibroblasts, indicating effects of myeloma treatment on CAFs [80]. Here, CD44 is linked to plasma cell myeloma.